Denali Therapeutics (DNLI) Operating Leases (2019 - 2026)

Denali Therapeutics (DNLI) has 8 years of Operating Leases data on file, last reported at $24.7 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $24.7 million, down 42.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.7 million (down 42.65% YoY), and the FY2025 annual result was $27.2 million, down 25.8% from the prior year.
• Operating Leases eased to $24.7 million in Q1 2026 per DNLI's latest filing, from $27.2 million in the prior quarter.
• Over five years, Operating Leases peaked at $62.7 million in Q1 2022 and troughed at $24.7 million in Q1 2026.
• A 5-year average of $44.4 million and a median of $46.9 million in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2026: Operating Leases rose 0.0% in 2024, then tumbled 42.65% in 2026.
• A 5-year view of Operating Leases shows it stood at $53.0 million in 2022, then fell by 15.18% to $45.0 million in 2023, then retreated by 18.47% to $36.7 million in 2024, then slipped by 25.8% to $27.2 million in 2025, then slipped by 9.3% to $24.7 million in 2026.
• Business Quant data shows DNLI's Operating Leases at $24.7 million in Q1 2026, $27.2 million in Q4 2025, and $29.7 million in Q3 2025.